This is a publisher's correction to an article titled "Clinical Development of Cancer Vaccines" published in Nature Medicine.[1] The original article is a review that discusses the clinical development of cancer vaccines and suggests a road map for their future development.[1] The authors emphasize the need for better strategies to expand the repertoire of tumor-reactive T cells in a safe, selective and efficient manner.[1] Cancer vaccines have potential, but the success of vaccines against infectious diseases has not yet been demonstrated in oncology.[1] Recent promising preliminary results from phase 1 and 2 clinical trials have renewed interest and launched large-scale cancer vaccine trials.[1] Key strategies include selecting high-quality antigens, especially neoantigens, modular vaccine platforms with an immune stimulus, and targeting early-stage cancers such as adjuvant therapies.[1] The article was published online on 11 March 2026 with DOI 10.1038/s41591-026-04241-9.[1]